Real World Experience –Stopping Study in Chronic Myeloid Leukemia

Real World Experience –Stopping Study in Chronic Myeloid Leukemia

Real World Experience –Stopping Study in Chronic Myeloid Leukemia

Dr. Caroline Hamm

Windsor Regional Hospital

FUNDER: WE-SPARK Health Institute


Related Programs:
Nucleus Cores:


Windsor Regional Cancer Centre

  • Dr. Indryas Woldie

  • Dr. Mohamad Jarrar

  • Dr. Rasna Gupta

  • Dr. Sindu Kanjeekal


Schulich School of Medicine

  • Greg Yousif

Project Description

Chronic Myeloid Leukemia (CML) is a chronic leukemia, often identified in asymptomatic people with a median age of diagnosis in Canada of 64 years. It accounts for 15% of all leukemias. Previous to the introduction of oral tyrosine kinase inhibitors (TKI’s) such as imatinib (Gleevec®) in 2001, 8-year survival was 15% following diagnosis. The use of TKI’s has led to an 8-year overall survival rate reaching 87%, thus nearly matching age matched controls. With this, the prevalence of CML has continued to rise with a predicted 112,000 in the USA this year.

Current guidelines recommend lifelong TKI treatment to maintain a deep and sustained molecular response (DMR). Despite the excellent success of TKI treatment, a therapeutic option for CML is the concept of stopping TKI treatment in patients to enter treatment-free-remission (TFR). The results from several clinical trials suggest that approximately half of the patients can remain in remission after stopping their TKI treatment once they achieve a deep molecular response and meet specific laboratory parameters. This is of immense clinical significance because there are many issues that come with life-long use of TKI therapy.

Our goal is to test a new paradigm for stopping TKIs in CML patients. This paradigm is one that will be more universally accessible for patients across Canada. This pilot trial will be the basis of a larger trial in Ontario.